Biomea Fusion Inc BMEA
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if BMEA is a good fit for your portfolio.
News
-
Biomea Fusion, Inc. Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
-
Biomea Fusion Highlights Initial Data from the First Two Type 1 Diabetes Patients Dosed with BMF-219
-
Biomea Fusion Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Highlights
-
Biomea Fusion Presents Patient Cohorts in COVALENT-111 Displaying a Durable Placebo-Adjusted Mean Reduction of up to 1.4% in HbA1c While Off Therapy at Week-26, after BMF-219’s 28-Day Treatment Cycle, Supporting Improved Pancreatic Function
-
Biomea Fusion, Inc. Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
-
Biomea Fusion stock soars after release of clinical data on diabetes treatment
-
Biomea Fusion Receives FDA Clearance for Leukemia Inhibitor's Investigational New Drug App
-
Biomea Fusion stock pulls back after $125 million stock offering follows record rally
Trading Information
- Previous Close Price
- $10.47
- Day Range
- $10.39–10.90
- 52-Week Range
- $8.13–43.69
- Bid/Ask
- $10.48 / $10.78
- Market Cap
- $386.89 Mil
- Volume/Avg
- 583,288 / 1.1 Mil
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Biomea Fusion Inc is a preclinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of irreversible small molecule drugs to treat patients with genetically defined cancers. The company's product candidate, BMF-219, is designed to be an orally bioavailable, potent and selective irreversible inhibitor of menin, an important transcriptional regulator known to play a direct role in oncogenic signaling in multiple cancers.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- 103
- Website
- https://www.biomeafusion.com
Comparables
Valuation
|
Metric
|
BMEA
|
CELC
|
VRDN
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 2.28 | 2.91 | 2.95 |
Price/Sales | — | — | 1,835.80 |
Price/Cash Flow | — | — | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
BMEA
|
CELC
|
VRDN
|
|---|---|---|---|
Quick Ratio | 7.74 | 12.78 | 17.93 |
Current Ratio | 7.84 | 13.43 | 18.26 |
Interest Coverage | — | −12.43 | −137.76 |
Quick Ratio
BMEA
CELC
VRDN
Profitability
|
Metric
|
BMEA
|
CELC
|
VRDN
|
|---|---|---|---|
Return on Assets (Normalized) | −56.31% | −35.57% | −42.76% |
Return on Equity (Normalized) | −65.70% | −49.08% | −82.42% |
Return on Invested Capital (Normalized) | −67.02% | −39.21% | −50.70% |
Return on Assets
BMEA
CELC
VRDN
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Zfrhxtsvbw | Hkxz | $554.7 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Bsqfcqzyb | Fvqhgw | $102.7 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Szmgsthq | Pdbjb | $97.8 Bil | |
MRNA
| Moderna Inc | Xqnfvpqj | Yfyf | $41.3 Bil | |
ARGX
| argenx SE ADR | Csblhgxk | Nlgt | $22.3 Bil | |
BNTX
| BioNTech SE ADR | Mhztvflb | Bmc | $21.0 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Ppbkfmdm | Lwjzm | $18.2 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Kjpmwpg | Xzwtzv | $15.4 Bil | |
RPRX
| Royalty Pharma PLC Class A | Ccbgchvbh | Swdjm | $12.5 Bil | |
INCY
| Incyte Corp | Jwswwjvl | Wkypqf | $11.6 Bil |